Journal of Cancer Clinical Trials

ISSN: 2577-0535

Open Access

Current Issue

Volume 5, Issue 2 (2020)

    Editor Note Pages: 1 - 1

    Cancer Pandemic and Cancer Clinical Trails

    Mari Uyeda

    Share this article
    2020 Conference Announcement Pages: 1 - 1

    Challenges for Oncology during the COVID-19

    Salah Aref

    Share this article
    Clinical image Pages: 1 - 2

    Lung Cancer Symptoms, Causes and Diagnosis

    Jorge P Grondona

    Share this article
    Market Analysis Pages: 1 - 2

    Global Summit on Cancer Research June 15-16, 2020 Barcelona, Spain

    Salah Aref

    Share this article

    Volume 5, Issue 3 (2020)

      Editorial Pages: 1 - 1

      Cancer Clinical Trails

      Hem D. Shukla

      The research studies that involve people is called Clinical trials through which doctors find new ways to improve treatments and the quality of life for people with disease. In this researchers design cancer clinical trials to test new ways to: • Treat cancer • Find and diagnose cancer • Prevent cancer • Manage symptoms of cancer and side effects from its treatment Clinical trials are the ultimate step during a long process that begins with research in a lab. Before any new treatment is employed with people in clinical trials, researchers work for several years to know its effects on cancer cells within the lab and in animals. They also try to figure out the side effects it may cause. This can also be a new drug, or combination of medicine or a special way of using established therapies. There are trials that involve new approaches to surgery and radiotherapy. There are clinical trials for each sort of cancer. While many trials specialize in late stage disease, there also are trials to stop cancer, improve early diagnosis, stop the cancer from returning, reduce side effects or improve quality of life.

      Short Communication Pages: 1 - 2

      The Cancer Cells

      Massimo Libra*

      Research on the biology of cancer starts with the only of questions: What is—and isn’t—normal? To understand how cancer develops and progresses, researchers first got to investigate the biological differences between normal cells and cancer cells. This work focuses on the mechanisms that underlie fundamental processes like cell growth, the transformation of normal cells to cancer cells, and therefore the spread (metastasis) of cancer cells.

      Short Communication Pages: 1 - 2

      Clinical Presentation and Management of Osteosarcoma

      Tarik Zine Belhocine*

      Osteosarcoma (OS) is the commonest sort of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the result for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to elucidate the resistance of OS to chemotherapy is that the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the traditional cells that acquire the primary cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage are proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is that the rationale for several recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies ready to target OS-CSCs.

      Short Communication Pages: 1 - 2

      Treatment for Disease Glioblastoma

      Antonio Russo

      Glioblastoma is an aggressive kind of cancer which can occur within the brain or spinal cord . Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age, but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting and seizures. Glioblastoma, also mentioned as glioblastoma multiforme, are often very difficult to treat and a cure is typically impossible . Treatments may slow progression of the cancer and reduce signs and symptoms.

      Research Pages: 1 - 4

      Knowledge, Attitude and Practice of Indian Oncology Residents on Clinical Trials: An Observational Study

      Ranjith Kumar CS ,Ponraj M, Jogmaya P, Dhanraju KM, Naresh Jadav, Jagdeep Singh, Smita Kayal, Biswajit Dubashi and Sunu Cyriac

      Background and objectives: A limiting factor in cancer treatment and prevention has been an inadequate accrual of patients onto clinical trials this more so in India and developing countries may be because of majority of trials will be done as dissertation of an oncology fellow. Many oncology training institutions are not having training curriculum regarding clinical trial design and basic statistical training which are barriers for accrual of patient in trials. Therefore, we aimed to assess the knowledge, attitude and practice of oncology residents on clinical trials across the country to improve the curriculum methodology so that we can produce better data on clinical trials. Methods: A total 50 students were recruited across the country; students were interviewed either directly or through telephonic conversation. Minimum criteria to enroll in the study was to have at least 1 year of working knowledge in oncology institute (only senior residents were included).Verbal informed consent was obtained from all the study participants. Results: All residents participated in the study know that clinical research is imperative, however only 30 (60%) of them showed interest towards cancer clinical trials. Thirty (60%) of the participants depending on western data for their patient management.36 (73%) participants felt that they were not able to interpret the data given in clinical trials. Only 6 (11%) of the participants had access to all cancer related journals. Though 35 (70%) of the participants discuss published clinical trials every week, only 25 (50%) of the residents are changing their decision based on clinical trial data during their patient management. Conclusions: In our study it was found that the resident doctors felt that clinical research is imperative in delivering appropriate management in malignant diseases. However, they had displeasing knowledge on health research. They have positive attitude towards cancer research, but they are failing to implement due to lack of training curriculum.

    Relevant Topics


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward